<p>馬薩諸塞州劍橋市 --（商業資訊）--Enveric Biosciences, Inc.（納斯達克：ENVB）（“Enveric” 或 “公司”）是一家生物技術公司，致力於開發下一代神經可塑性小分子，以應對精神和神經疾病。今天，公司宣佈已完成之前宣佈的行使某些未到期認股權證的交易，購買總計 426,390 股，最初於 2025 年 2 月和 2025 年 9 月發行，行使價格分別為每股 36.00 美元和 10.98 美元，現以每股 7.05 美元的降低行使價格進行行使。根據有效的 S-1 表格（編號 333-284277）和 S-3 表格（編號 333-290580）註冊聲明，行使認股權證後可發行的普通股已註冊。公司從行使認股權證中獲得的總收益約為 310 萬美元，未扣除承銷商費用和預計的發行費用。</p>
<p>H.C. Wainwright &amp; Co. 擔任此次發行的獨家承銷商。</p>
<p>作為立即以現金行使認股權證的對價，並支付每個新未註冊認股權證額外 0.125 美元（總計 106,597.50 美元，已包含在公司總收益中），公司發行了新的未註冊 E 系列認股權證，購買最多 426,390 股普通股，以及新的未註冊 F 系列認股權證，購買最多 426,390 股普通股。新的 E 系列認股權證的行使價格為每股 7.05 美元，可立即行使，並將在轉售註冊聲明生效後五年到期。新的 F 系列認股權證的行使價格為每股 7.05 美元，可立即行使，並將在轉售註冊聲明生效後十八個月到期。</p>
<p>公司計劃將此次發行的淨收益用於產品開發、營運資金和一般企業用途。</p>
<p>上述新認股權證是在適用的證券法 1933 年修正案（“1933 年法”）的註冊要求豁免下進行的私募發行，並且與行使後可發行的普通股一起，尚未根據 1933 年法進行註冊，且在未向證券交易委員會（“SEC”）註冊或獲得適用的豁免之前，不能在美國進行要約或銷售。公司已同意向 SEC 提交一份註冊聲明，涵蓋行使新認股權證後可發行的普通股的轉售（“轉售註冊聲明”）。</p>
<p>本新聞稿不構成出售或招攬購買此處描述的任何證券的要約，也不應在任何州或其他司法管轄區進行這些證券的銷售，除非在任何此類州或其他司法管轄區的證券法下進行註冊或資格認證。</p>
<p><strong>關於 Enveric Biosciences</strong></p>
<p>Enveric Biosciences（納斯達克：ENVB）是一家生物技術公司，專注於開發下一代小分子神經可塑性治療藥物，以滿足精神和神經疾病的未滿足需求。通過利用差異化的藥物發現平台和不斷增長的專利保護化學結構庫，Enveric 正在推進一系列新型化合物的研發，旨在促進神經可塑性而不產生迷幻效果。Enveric 的主要候選藥物 EB-003 是首個已知的化合物，旨在選擇性地作用於 5-HT₂A 和 5-HT₁B 受體，具有快速、持久的抗抑鬱和抗焦慮效果，並便於門診使用。</p>
<p>欲瞭解更多信息，請訪問 www.enveric.com。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含適用證券法意義上的前瞻性陳述和前瞻性信息。這些陳述涉及未來事件或未來表現。除歷史事實陳述外的所有陳述均可能是前瞻性陳述或信息。通常，前瞻性陳述和信息可以通過使用前瞻性術語來識別，例如 “計劃”、“預期” 或 “未預期”、“提議”、“預算”、“探索”、“安排”、“尋求”、“估計”、“預測”、“打算”、“預期” 或 “未預期”，或 “相信”，或這些詞語和短語的變體，或通過使用表明某些行動、事件或結果可能、能夠、應該、會或可能發生或實現的詞語或短語。前瞻性陳述可能包括關於未來的信念、計劃、期望或意圖的陳述，並基於管理層的信念以及管理層所做的假設和當前可用的信息，包括但不限於關於預期使用發行收益的陳述。實際結果可能因某些因素而與前瞻性陳述所設想的結果有重大差異，包括但不限於，Enveric 能否：最終確定並提交其 IND 申請給美國食品藥品監督管理局；成功開展臨牀項目；實現技術發展所設想的價值創造；避免計劃臨牀試驗的延誤；在臨牀前或臨牀試驗中證明潛在產品的有效性或安全性；建立或維持治療候選藥物開發的合作關係；獲得適當或必要的政府批准以市場潛在產品；以商業合理的條款獲得未來產品開發和營運資金；擴大產品候選藥物的生產；應對競爭對手規模和性質的變化；招聘和留住關鍵高管和科學家；確保和維護與 Enveric 產品相關的法律權利，包括專利保護；識別並追求從其研發管道資產中獲取價值的替代途徑；繼續作為持續經營的企業；以及有效管理其未來增長。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI4NDQ1NTByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI4NDQ1NTByMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212844550/en/</p>
<p>投資者關係</p>
<p>Tiberend Strategic Advisors, Inc.</p>
<p>David Irish</p>
<p>(231) 632-0002</p>
<p>dirish@tiberend.com</p>
<p>媒體關係</p>
<p>Tiberend Strategic Advisors, Inc.</p>
<p>Casey McDonald</p>
<p>(646) 577-8520</p>
<p>cmcdonald@tiberend.com</p>
<p>來源：Enveric Biosciences, Inc.</p>

ENVB

<p>Enveric Biosciences 宣佈完成其認股權證的行使，籌集了 310 萬美元的總收入。此次行使涉及 426,390 股，行使價格為每股 7.05 美元。新發行的未註冊 E 系列和 F 系列認股權證的收益將用於產品開發和公司用途。H.C. Wainwright & Co. 擔任了配售代理。新認股權證是在私募中提供的，並未根據 1933 年法案註冊。Enveric 計劃提交註冊聲明以便轉售股份</p>

<p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 426,390 shares originally issued in February 2025 and September 2025, having exercise prices of $36.00 and $10.98 per share, respectively, at a reduced exercise price of $7.05 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1 (No. 333-284277) and Form S-3 (No. 333-290580). The gross proceeds to the Company from the exercise of the warrants were approximately $3.1 million, prior to deducting placement agent fees and estimated offering expenses.</p>
<div class="lb-trans"><p>馬薩諸塞州劍橋市 --（商業資訊）--Enveric Biosciences, Inc.（納斯達克：ENVB）（“Enveric” 或 “公司”）是一家生物技術公司，致力於開發下一代神經可塑性小分子，以應對精神和神經疾病。今天，公司宣佈已完成之前宣佈的行使某些未到期認股權證的交易，購買總計 426,390 股，最初於 2025 年 2 月和 2025 年 9 月發行，行使價格分別為每股 36.00 美元和 10.98 美元，現以每股 7.05 美元的降低行使價格進行行使。根據有效的 S-1 表格（編號 333-284277）和 S-3 表格（編號 333-290580）註冊聲明，行使認股權證後可發行的普通股已註冊。公司從行使認股權證中獲得的總收益約為 310 萬美元，未扣除承銷商費用和預計的發行費用。</p>
</div><p>H.C. Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</p>
<div class="lb-trans"><p>H.C. Wainwright &amp; Co. 擔任此次發行的獨家承銷商。</p>
</div><p>In consideration for the immediate exercise of the warrants for cash and the payment of additional $0.125 per new unregistered warrant (additional $106,597.50 in the aggregate, which are included in the gross proceeds to the Company), the Company issued new unregistered series E warrants to purchase up to 426,390 shares of common stock and new unregistered series F warrants to purchase up to 426,390 shares of common stock. The new series E warrants have an exercise price of $7.05 per share, are exercisable immediately and will expire five years after the effective date of the Resale Registration Statement (as defined below). The new series F warrants have an exercise price of $7.05 per share, are exercisable immediately and will expire eighteen months after the effective date of the Resale Registration Statement.</p>
<div class="lb-trans"><p>作為立即以現金行使認股權證的對價，並支付每個新未註冊認股權證額外 0.125 美元（總計 106,597.50 美元，已包含在公司總收益中），公司發行了新的未註冊 E 系列認股權證，購買最多 426,390 股普通股，以及新的未註冊 F 系列認股權證，購買最多 426,390 股普通股。新的 E 系列認股權證的行使價格為每股 7.05 美元，可立即行使，並將在轉售註冊聲明生效後五年到期。新的 F 系列認股權證的行使價格為每股 7.05 美元，可立即行使，並將在轉售註冊聲明生效後十八個月到期。</p>
</div><p>The Company intends to use the net proceeds from the offering for product development, working capital and general corporate purposes.</p>
<div class="lb-trans"><p>公司計劃將此次發行的淨收益用於產品開發、營運資金和一般企業用途。</p>
</div><p>The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants (the “Resale Registration Statement”).</p>
<div class="lb-trans"><p>上述新認股權證是在適用的證券法 1933 年修正案（“1933 年法”）的註冊要求豁免下進行的私募發行，並且與行使後可發行的普通股一起，尚未根據 1933 年法進行註冊，且在未向證券交易委員會（“SEC”）註冊或獲得適用的豁免之前，不能在美國進行要約或銷售。公司已同意向 SEC 提交一份註冊聲明，涵蓋行使新認股權證後可發行的普通股的轉售（“轉售註冊聲明”）。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售或招攬購買此處描述的任何證券的要約，也不應在任何州或其他司法管轄區進行這些證券的銷售，除非在任何此類州或其他司法管轄區的證券法下進行註冊或資格認證。</p>
</div><p><strong>About Enveric Biosciences</strong></p>
<div class="lb-trans"><p><strong>關於 Enveric Biosciences</strong></p>
</div><p>Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of patent protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors with the potential to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.</p>
<div class="lb-trans"><p>Enveric Biosciences（納斯達克：ENVB）是一家生物技術公司，專注於開發下一代小分子神經可塑性治療藥物，以滿足精神和神經疾病的未滿足需求。通過利用差異化的藥物發現平台和不斷增長的專利保護化學結構庫，Enveric 正在推進一系列新型化合物的研發，旨在促進神經可塑性而不產生迷幻效果。Enveric 的主要候選藥物 EB-003 是首個已知的化合物，旨在選擇性地作用於 5-HT₂A 和 5-HT₁B 受體，具有快速、持久的抗抑鬱和抗焦慮效果，並便於門診使用。</p>
</div><p>For more information, please visit www.enveric.com.</p>
<div class="lb-trans"><p>欲瞭解更多信息，請訪問 www.enveric.com。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “explores,” “schedules,” “seeks,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management, including, but not limited to, statements regarding the anticipated use of proceeds from the offering. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.</p>
<div class="lb-trans"><p>本新聞稿包含適用證券法意義上的前瞻性陳述和前瞻性信息。這些陳述涉及未來事件或未來表現。除歷史事實陳述外的所有陳述均可能是前瞻性陳述或信息。通常，前瞻性陳述和信息可以通過使用前瞻性術語來識別，例如 “計劃”、“預期” 或 “未預期”、“提議”、“預算”、“探索”、“安排”、“尋求”、“估計”、“預測”、“打算”、“預期” 或 “未預期”，或 “相信”，或這些詞語和短語的變體，或通過使用表明某些行動、事件或結果可能、能夠、應該、會或可能發生或實現的詞語或短語。前瞻性陳述可能包括關於未來的信念、計劃、期望或意圖的陳述，並基於管理層的信念以及管理層所做的假設和當前可用的信息，包括但不限於關於預期使用發行收益的陳述。實際結果可能因某些因素而與前瞻性陳述所設想的結果有重大差異，包括但不限於，Enveric 能否：最終確定並提交其 IND 申請給美國食品藥品監督管理局；成功開展臨牀項目；實現技術發展所設想的價值創造；避免計劃臨牀試驗的延誤；在臨牀前或臨牀試驗中證明潛在產品的有效性或安全性；建立或維持治療候選藥物開發的合作關係；獲得適當或必要的政府批准以市場潛在產品；以商業合理的條款獲得未來產品開發和營運資金；擴大產品候選藥物的生產；應對競爭對手規模和性質的變化；招聘和留住關鍵高管和科學家；確保和維護與 Enveric 產品相關的法律權利，包括專利保護；識別並追求從其研發管道資產中獲取價值的替代途徑；繼續作為持續經營的企業；以及有效管理其未來增長。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMTI4NDQ1NTByMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251212844550r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251212844550/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251212844550/en/</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>Tiberend Strategic Advisors, Inc.</p>
<div class="lb-trans"><p>Tiberend Strategic Advisors, Inc.</p>
</div><p>David Irish</p>
<div class="lb-trans"><p>David Irish</p>
</div><p>(231) 632-0002</p>
<div class="lb-trans"><p>(231) 632-0002</p>
</div><p>dirish@tiberend.com</p>
<div class="lb-trans"><p>dirish@tiberend.com</p>
</div><p>Media Relations</p>
<div class="lb-trans"><p>媒體關係</p>
</div><p>Tiberend Strategic Advisors, Inc.</p>
<div class="lb-trans"><p>Tiberend Strategic Advisors, Inc.</p>
</div><p>Casey McDonald</p>
<div class="lb-trans"><p>Casey McDonald</p>
</div><p>(646) 577-8520</p>
<div class="lb-trans"><p>(646) 577-8520</p>
</div><p>cmcdonald@tiberend.com</p>
<div class="lb-trans"><p>cmcdonald@tiberend.com</p>
</div><p>Source: Enveric Biosciences, Inc.</p>
<div class="lb-trans"><p>來源：Enveric Biosciences, Inc.</p>
</div>

Enveric Biosciences 宣佈完成認股權證的行使，獲得 310 萬美元的總收益 | ENVB 股票新聞